Search Results

Scientists from Colossal Biosciences, the world’s first de-extinction company, and the University of Melbourne announce a major step forward in the effort to save Australia’s endangered northern quoll from the invasive cane toad.

Crossject, a specialty pharma company developing needle-free auto-injectors for emergency situations, announces it has concluded a commercialization agreement in northern Europe for its innovative rescue therapy for epileptic seizures ZEPIZURE®, previously known as ZENEO® Midazolam, covering Germany, the UK, Denmark, Sweden, Finland and Norway.

The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s manufacturing operations in Ireland.

Colossal Biosciences, the world’s first de-extinction company, and BioRescue, a consortium initiating and leading the scientific rescue mission of the northern white rhino employing advanced assisted reproduction technologies and stem cell associated techniques, have teamed up to save the northern white rhino from extinction.

Drug development powered by artificial intelligence is countering incentives from the Inflation Reduction Act and making small molecules more attractive in the complex inflammatory & immunology disease space.